drugset / Trial / NCT04448886
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Phase 2
Active not recruiting
110 enrolled
Ana C Garrido-Castro, MD
Gilead Sciences · collabMerck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study is evaluating the safety and effectiveness of Sacituzumab Govitecan with or without Pembrolizumab in metastatic HR+/HER2- breast cancer. The names of the study interventions involved in this study are: * Sacituzumab govitecan (IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)
Timeline
- Start
- 2020-09-23
- Primary completion
- 2024-03-09
- Completion
- 2027-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | Sacituzumab Govitecan | Monoclonal antibody | — | Intravenous |